KRON News and Press, Kronos Bio Inc. From 11/14/23

2023-11-14 02:12:30 ET More on Kronos Bio Kronos to cut 19% of workforce, focus on drugs KB-0742, lanraplenib Kronos Bio stock slightly up on positive preliminary data for investigational cancer drug Seeking Alpha’s Quant Rating on Kronos Bio Historica...

Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences Optimization of resource allocation, restructuring and cost containment extends runway into 2026 Company on track to provide...

2023-11-02 16:47:29 ET More on Kronos Bio Kronos Bio stock slightly up on positive preliminary data for investigational cancer drug Kronos Bio announces departure of CFO, Head of Corporate Development Al-Wakeel Seeking Alpha’s Quant Rating on Kronos Bio ...

Strategic resource allocation to fully explore KB-0742’s potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study Restructuring plan extends anticipated cash runway into 2026 Company to continue with lanraplenib deve...

Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studies at leading international sarcoma meeting KB-0742 demonstrated on-me...

Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to tr...

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4 neutropenia, dose proportional exposure, dose-dependent target engagement, and 24-hour plasma...

SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., fol...

2023-08-17 08:59:28 ET More on Kronos Bio Kronos Bio gains as CEO buys over $2 million worth of shares Kronos Bio to start Phase 3 trial for Entospletinib in AML Kronos Bio on go with early-stage cancer study with KB-0742 Seeking Alpha’s Quant Rating o...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign ...